CD8<sup>+</sup> T cells mediate protection against Zika virus induced by an NS3-based vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33148638.
- Also identified by DOI 10.1126/sciadv.abb2154 and PMC identifier 7673678.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Zika virus (ZIKV) is associated with congenital malformations in infants born to infected mothers, and with Guillain-Barré syndrome in infected adults. Development of ZIKV vaccines has focused predominantly on the induction of neutralizing antibodies, although a suboptimal antibody response may theoretically enhance disease severity through antibody-dependent enhancement (ADE). Here, we report induction of a protective anti-ZIKV CD8<sup>+</sup> T cell response in the HLA-B*0702 <i>Ifnar1<sup>-/-</sup></i> transgenic mice using an alphavirus-based replicon RNA vaccine expressing ZIKV nonstructural protein NS3, a potent T cell antigen. The NS3 vaccine did not induce a neutralizing antibody response but elicited polyfunctional CD8<sup>+</sup> T cells that were necessary and sufficient for preventing death in lethally infected adult mice and fetal growth restriction in infected pregnant mice. These data identify CD8<sup>+</sup> T cells as the major mediators of ZIKV NS3 vaccine-induced protection and suggest a new strategy to develop safe and effective anti-flavivirus vaccines.
Medical subject headings
- Zika Virus
- Zika Virus Infection